To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Bladder Cancer

Katie Kosko
A new study links e-cigarette use to bladder cancer but experts say more research is needed.
Conor Killmurray
There are a number of treatment options available for patients with urothelial cancer, however, experts want to refine the current treatment paradigm amid new drugs entering the landscape.
Katie Kosko
Treatment for patients with bladder cancer is moving away from VEGF-targeted therapies toward immune checkpoint inhibition, according to one expert.
Jonathan Rosenberg, M.D.
The results of a phase 2 study looking at Padcev and Keytruda combination therapy for patients with metastatic urothelial cancer shows promise with a 73% response that did not differ for a patient’s PDL1 status.
Kristie L. Kahl
The combination of Padcev plus Keytruda induced a high rate of durable objective response rates in patients with locally advanced or metastatic urothelial cancer.
Kristie L. Kahl
A new study supported the use of a blood test to detect clusters of cancer cells in the blood of asymptomatic individuals, meaning, patients could have a non-invasive screening and testing method.
Katie Kosko
Better response rates may be seen in patients with advanced bladder cancer when two therapies are combined.
The Bladder Cancer Advocacy Network announces it's Bladder Cancer Research Innovation Award.
FDA has given an accelerated approval to Padcev in the treatment of patients with locally advanced or metastatic urothelial cancer.
Bladder Cancer Advocacy Network
The Bladder Cancer Advocacy Network (BCAN) is pleased to announce two 2020 Young Investigator Awards (YIA), to support the development of outstanding early-career research scientists and clinical cancer research investigators.

Sign In

Not a member? Sign up now!
Continue without login